The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...

Ogsiveo ™ met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease ...

The Food and Drug Administration (FDA) has approved Ogsiveo ™ (nirogacestat) for adult patients with progressing desmoid tumors who require systematic treatment. Desmoid tumors, also known as ...

Confirmed objective response rate (ORR) based on RECIST v1.1 was 41% with Ogsiveo vs. 8% with placebo (p<0.001); the complete response rate was 7% in the Ogsiveo arm and 0% in the placebo arm.

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...